Insulin Resistance in Women With Prolactinoma

This study has been completed.
Sponsor:
Information provided by:
Universidade Federal do Rio de Janeiro
ClinicalTrials.gov Identifier:
NCT00481299
First received: May 30, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted
  Purpose

Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma.

The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.


Condition
Prolactinoma
Insulin Resistance
Hyperlipidemia

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists

Resource links provided by NLM:


Further study details as provided by Universidade Federal do Rio de Janeiro:

Enrollment: 2004
Study Start Date: October 2004
Study Completion Date: September 2006
Detailed Description:

A cross-sectional study was performed in non-obese premenopausal women with prolactinoma treated with dopamine agonists evaluated regarding glucose, insulin, Homeostasis Model Assessment (HOMA), lipid profile, C reactive protein (CRP), body mass index (BMI), waist circumference, prolactin, estradiol, testosterone, and sex hormone binding globulin (SHBG). They were compared with control women of similar age and BMI distribution.

  Eligibility

Ages Eligible for Study:   18 Years to 48 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Prolactinoma
  • Female gender
  • Premenopausal

Exclusion Criteria:

  • Obesity (BMI ≥ 30 kg/m²)
  • Diabetes mellitus
  • Hypertension
  • GH deficiency
  • Hypothyroidism
  • Primary hypogonadism
  • Adrenal insufficiency
  • Pituitary surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00481299

Locations
Brazil
Clementino Fraga Filho University Hospital
Rio de Janeiro, RJ, Brazil
Sponsors and Collaborators
Universidade Federal do Rio de Janeiro
Investigators
Principal Investigator: Erika CO Naliato, MSc Federal University of Rio de Janeiro - Brazil
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00481299     History of Changes
Other Study ID Numbers: 178/04
Study First Received: May 30, 2007
Last Updated: May 30, 2007
Health Authority: Brazil: National Committee of Ethics in Research

Keywords provided by Universidade Federal do Rio de Janeiro:
Insulin
glucose
lipids
prolactinoma
hyperprolactinemia

Additional relevant MeSH terms:
Hyperlipidemias
Insulin Resistance
Prolactinoma
Adenoma
Brain Diseases
Central Nervous System Diseases
Dyslipidemias
Endocrine Gland Neoplasms
Endocrine System Diseases
Glucose Metabolism Disorders
Hyperinsulinism
Hypothalamic Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Nervous System Diseases
Pituitary Diseases
Pituitary Neoplasms
Insulin
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 29, 2014